Igc Pharma Inc (IGC) Stock Price, Quote & News

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MI...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 983 0998

Website: igcpharma.com

Address:

10224 Falls Road, Potomac, United States

Shawshank_book_keeper Aug. 19 at 2:49 PM

$IGC I hope this works out because I can go out to my local market and purchase CBD oil and melatonin over the counter and it’s basically the same thing!

0 · Reply

GordoHLYK13 Aug. 19 at 2:43 PM

$IGC $SPY $SPCX $SMCI $QQQ

0 · Reply

GordoHLYK13 Aug. 19 at 2:37 PM

$IGC Bull Case in a nutshell: The patented micro-dose THC + melatonin formulation is the key asset, targeting Alzheimer’s agitation through complementary pathways. IGC retains the rights, so a strong Q4 Phase 2 CALMA readout could dramatically de-risk IGC-AD1 and put the company on the radar for licensing, partnership, or acquisition interest. With a micro-cap valuation, even a $200M–$300M+ re-rating could translate into substantial per-share upside. The key catalyst is simple: statistically significant Phase 2 data = potential institutional interest, short covering, and Big Pharma negotiations. 🔥 The setup is binary: Q4 data is the catalyst. If CALMA hits, $2–$3+ becomes a plausible bull-case scenario—not a guarantee. $LABS $SCLX $GWPH $IGC stands out: Phase 2 CALMA, patented THC + melatonin formulation, and a Q4 2026 readout ahead. Positive THC/CBD data elsewhere only strengthens the cannabinoid-agitation thesis. Don’t underestimate $IGC—this setup could get very interesting. 🔥

0 · Reply

Shawshank_book_keeper Aug. 19 at 2:32 PM

$IGC

0 · Reply

_jaydub_ Aug. 19 at 2:29 PM

$IGC huge spike in volume on the 10 min

0 · Reply

RocketQueen Aug. 19 at 1:47 PM

$IGC think we could see some head twisting moves later this calendar year. Be prepared or miss out.

0 · Reply

GordoHLYK13 Aug. 19 at 11:25 AM

$IGC $IMNM $INTS $NUVB $SYRE https://youtu.be/ger_p3eVdQ0?is=okQ_sPh7UWGqutbj

1 · Reply

GordoHLYK13 Aug. 19 at 11:24 AM

$IGC The setup is getting very interesting. Phase 2 CALMA is nearing completion, enrollment has already exceeded the original target, and Q4 2026 topline results are the major catalyst. While the market is focused on the noise, I’m focused on the execution, the clinical catalyst, and the potential re-rating if IGC-AD1 delivers meaningful results. Add the AI/data platform, regulatory preparation, insider debt conversion, and a relatively small valuation—and the risk/reward starts getting interesting. This isn’t about hype; it’s about the catalyst ahead. If Phase 2 hits, $IGC could go from overlooked micro-cap to a serious biotech story very quickly. Shorts may be watching the chart, but bulls are watching the data 🚀🔥 Management has put $1.5 million on the line, showing strong confidence and alignment heading into the catalyst $NUVB $SYRE * $IMNM * $INTS Updates released one day ago https://youtu.be/ger_p3eVdQ0?is=L8PItIi_MIslLlvG

0 · Reply

GordoHLYK13 Aug. 19 at 8:09 AM

$IGC easy money why not take high risk high reward $IGC is entering a high-stakes catalyst window 🚀 Phase 2 CALMA enrollment is essentially complete, with Q4 2026 topline data ahead. Cash and dilution risks are real—but if IGC-AD1 delivers positive results in Alzheimer’s agitation, the clinical catalyst could completely change the valuation narrative. 🔥📈 https://www.tipranks.com/news/the-fly/igc-pharma-reports-q2-eps-3c-vs-2c-last-year-thefly-news

0 · Reply

Tradingistheway Aug. 19 at 6:42 AM

$IGC block this dude he was just bullish

1 · Reply

Market Cap	28.03M
Revenue (ttm)	1.27M
Net Income (ttm)	-7.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.15

Volume	529,900
Avg Vol	603,162
Day's Range	N/A - N/A
Shares Out	100.09M
Stochastic %K	68%
Beta	0.45
Analysts	Sell
Price Target	$4.25